VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ALBT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ALBTAvalon GloboCare Corp.
$0.29$1M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ALBT logoAvalon GloboCare Corp.(ALBT)Earnings, Financials & Key Ratios

ALBT•NASDAQ
$0.29
Price updated Jul 6, 2026
SectorReal EstateIndustryReal Estate ServicesSub-IndustryReal estate owners and developers
AboutAvalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.Show more
  • Revenue$0-100.0%
  • EBITDA-$7M-60.6%
  • Net Income-$18M-131.1%
  • EPS (Diluted)-5.64+33.2%
  • ROE-223.61%-104.7%

ALBT Price & Volume

Avalon GloboCare Corp. (ALBT) stock price & volume — 10-year historical chart

Loading chart...

Operational Pivot Triggers Severe Liquidity Contraction Risk

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion

Key Thesis Takeaways

  • Avalon GloboCare Corp.
  • is currently undergoing a high-risk transition from legacy real estate services to a speculative biotechnology licensing model, characterized by a total cessation of revenue as of 2026Q1.
  • The firm's financial stability is severely compromised by a $110.4 million retained earnings deficit and a reliance on intangible assets, with goodwill representing $12.8 million of the $16.2 million total asset base.
  • Investors should exercise extreme caution as the company faces an imminent liquidity inflection point that likely necessitates further dilutive financing to sustain its $1.9 million quarterly SG&A overhead.

Verdict Logic

the company's current ratio of 0.38 and the total absence of revenue in 2026Q1 suggest an imminent risk of insolvency or severe shareholder dilution.

ALBT Growth Metrics

Avalon GloboCare Corp. (ALBT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-125.56%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-116.42%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-33.01%

Return on Capital

10 Years-95.59%
5 Years-90.93%
3 Years-81.66%
Last Year-92.83%

ALBT Recent Earnings

Avalon GloboCare Corp. (ALBT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
Q2 2026Latest
May 11, 2026
Metric
Actual
Est
EPS
$0.49
—
Rev
—
—
Q1 2026
Feb 13, 2026
Metric
Actual
Est
EPS
$0.43
—
Rev
$1M
—
Q4 2025
Nov 14, 2025
Metric
Actual
Est
EPS
$0.06
—
Rev
$350,099
—
Q3 2025
Aug 14, 2025
Metric
Actual
Est
EPS
$2.02
—
Rev
$350,406
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 11, 2026
$0.49
—
Q1 2026Feb 13, 2026
$0.43
$1M
Q4 2025Nov 14, 2025
$0.06
$350,099
Q3 2025Aug 14, 2025
$2.02
$350,406
Based on last 12 quarters of dataView full earnings history →

Latest ALBT News

Recent stock market news and headlines for Avalon GloboCare Corp. (ALBT)

GlobeNewsWire·Jun 16, 2026
Chief Patrick Flannelly Highlights KetoAir™ Progress in Supporting the Nevada First Responders Holistic Health Reset Program

FREEHOLD, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today provided an update on the Nevada POOL/PACT Holistic Health Reset program launched in collaboration with Saga Health and SpecialtyHealth, Inc. The four-month wellness initiative, which began in August 2025, was designed to support 50 first responders through a comprehensive health optimization program focused on improving metabolic, physical, and behavioral wellness outcomes.

Peers Comparison

Key metrics vs top competitors for Avalon GloboCare Corp. (ALBT)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ALBT logoALBTAvalon GloboCare Corp.Current
$0.29$1.24M-0.05-100%—-223.61%—
CELC logoCELCCelcuity Inc.
$108.58$5.3B-28.72——-244.61%—
NKTR logoNKTRNektar Therapeutics
$73.15$1.43B-7.52-43.89%-284.18%-87%—
SNGX logoSNGXSoligenix, Inc.
$0.38$3.97M-0.18——-246.04%—
FATE logoFATEFate Therapeutics, Inc.
$2.99$348.51M-2.60-51.24%-2056.79%-58.89%—
CRSP logoCRSPCRISPR Therapeutics AG
$61.89$5.97B-9.57-89.97%-13856.54%-30.88%—

Compare ALBT vs Peers

Avalon GloboCare Corp. (ALBT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CELC

Most directly comparable listed peer for ALBT.

Scale Benchmark

vs TMO

Larger-name benchmark to compare ALBT against a more recognizable public peer.

Peer Set

Compare Top 5

vs CELC, NKTR, SNGX, FATE

ALBT SEC Filings & Documents

Avalon GloboCare Corp. (ALBT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 21, 2026·SEC

Material company update

Apr 17, 2026·SEC

Material company update

Apr 2, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 30, 2026·SEC

FY 2025

Mar 31, 2025·SEC

10-Q Quarterly Reports

4
FY 2026

May 11, 2026·SEC

FY 2025

Nov 14, 2025·SEC

FY 2025

Aug 14, 2025·SEC

Get notified when ALBT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ALBT Frequently Asked Questions

Avalon GloboCare Corp. (ALBT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Avalon GloboCare Corp.'s revenue?

Avalon GloboCare Corp. (ALBT) reported $-0.3M in revenue for fiscal year 2025.

How fast is Avalon GloboCare Corp. growing?

Avalon GloboCare Corp. (ALBT) saw revenue decline by 100.0% over the past year.

Is ALBT profitable?

Avalon GloboCare Corp. (ALBT) reported a net loss of $19.5M for fiscal year 2025.

Dividend & Returns
What is ALBT's return on equity?

Avalon GloboCare Corp. (ALBT) has a return on equity (ROE) of -223.6%. Negative ROE indicates the company is unprofitable.

What is Avalon GloboCare Corp.'s free cash flow?

Avalon GloboCare Corp. (ALBT) had negative free cash flow of $6.4M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ALBT back in 2015?

Total return calculator · dividends reinvested · 11+ years of data

See returns →